<?xml version="1.0" encoding="UTF-8"?>
<p id="para20">HIV remains highly prevalent in sub-Saharan Africa with over 25·7 million (uncertainty range 22·2–29·5) people estimated to be living with HIV in the region in 2018.
 <xref rid="bib4" ref-type="bibr">
  <sup>4</sup>
 </xref> Concern exists that possible disruptions in HIV programmes due to COVID-19
 <xref rid="bib1" ref-type="bibr">1</xref>, 
 <xref rid="bib2" ref-type="bibr">2</xref>, 
 <xref rid="bib5" ref-type="bibr">5</xref> could affect HIV-related mortality and new infections. Negative effects of the COVID-19 epidemic on access to health services have begun to emerge. A survey of people living with HIV run by the Human Sciences Research Council in South Africa via a social media platform found that 13% of people said they did not have access to their chronic medication during lockdown,
 <xref rid="bib6" ref-type="bibr">
  <sup>6</sup>
 </xref> with some reports in the area as of May, 2020, showing that only 30–50% of patients were collecting their medication.
 <xref rid="bib7" ref-type="bibr">
  <sup>7</sup>
 </xref> A rapid survey assessment in Zimbabwe in April, 2020, found 19% of people with HIV attempting to get a refill of an antiretroviral drug had not been able to, or were only able to get a partial refill,
 <xref rid="bib8" ref-type="bibr">
  <sup>8</sup>
 </xref> while a telephone-based survey in Kenya and Nigeria run by the Finmark Trust in April, 2020, found 14% of people were unable to collect needed medications.
 <xref rid="bib9" ref-type="bibr">
  <sup>9</sup>
 </xref> In a May, 2020, WHO survey in five of 13 countries in sub-Saharan Africa, antiretroviral therapy (ART) stock availability for major first-line drugs was reported to be 3 months or less, with reasons including failure of suppliers to deliver on time (Low-Beer D, WHO, Geneva, Switzerland, personal communication).
</p>
